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Results 145 CD4+ T cell responses to B. anthracis PA epitopes in anthrax-recovered 146 patients and vaccinees 147 We have previously described T cell memory responses to anthrax antigens in a cohort 148 of individuals who suffered clinical disease after natural, occupational exposure [25, 26, 149 28]. These were agricultural workers from the Kayseri region of Turkey who had been in 150 contact with infected livestock and been hospitalised with confirmed cutaneous anthrax 151 infections. PBMCs were collected for immune analysis at 0.4 to 7.5 years after recovery 152 under antibiotic therapy. In earlier studies, we described the fact that responses to 153 recombinant PA and LF antigens were higher in naturally exposed individuals than in 154 vaccinees receiving a full course of the UK AVP anthrax vaccine. Furthermore, immune 155 responses in naturally infected donors were characterised by a broad cytokine profile, 156 encompassing IL-2, IL-5, . In the present study we sought to analyse 10 190 Figure 1 . 191 192 Differential susceptibility to B. anthracis challenge in HLA transgenic 193 mice 194 In order to more precisely define the contribution of different HLA class II alleles to 195 anthrax and PA immunity, we turned to HLA class II transgenic mice as a defined, 196 reductionist model allowing analysis of individual alleles in isolation. 197 198 We initially compared susceptibility of mice expressing either HLA-DR1 or HL-DQ8 to 199 challenge with 1x10 6 CFU (10 3 median lethal doses, MLD) B. anthracis STI strain. DR1 mice were resistant to B. anthracis STI challenge (MLD > 10 6 CFU), while HLA-201 DQ8 mice were also relatively resistant, with 80% survival. The more susceptible HLA 202 class II transgenic mice demonstrated differential susceptibility to challenge at 10 5 CFU 203 (10 2 MLD B. anthracis STI) with the following survival rates: DQ6 mice (100%), DR4 204 (80%), and DR15 (55%). By comparison, the parent strain for the HLA class II 205 transgenics, C57BL6, showed 40% survival against a 10 5 CFU contemporaneous 206 challenge with the STI vaccine strain of B. anthracis. The bacterial loads recovered from the spleens of individual surviving mice of each strain 212 at day 20 are shown in Fig 2. In general the mean bacterial loads in spleens at day 20 213 post-infection were lower than, but proportional to, the original challenge dose level. The 214 groups challenged with 10 6 CFU (DR1, DQ8) had high bacterial loads, although the mean 215 bacterial loads for the DQ6 mice (challenged with 10 5 CFU) did not differ significantly 216 from those for the DR1 or DQ8 mice, which had been challenged with ten-fold more 217 bacteria, suggesting that the DQ6 mice were slower to clear the infection. 12 219 HLA transgenic mice were less susceptible to infection with B. anthracis STI strain than 220 the parent strain C57BL6 mice. HLA-DR1 mice were resistant to infection with a high- 221 level challenge (10 6 CFU). DQ6 strain mice were resistant to 10 5 CFU and relatively slow 222 to clear the infection. The order of susceptibility of mouse strains to B. anthracis 223 infection was determined to be: C57Bl6 > DR15 > DR4 > DQ6 > DQ8 > DR1. 224 
225
CD4 + T cell responses to B. anthracis PA epitopes in HLA transgenic mice 226 The greater immunogenetic complexity of HLA-outbred human populations makes it 227 considerably more challenging to define the restricting HLA molecule responsible for 228 antigen presentation; the HLA class II transgenic mouse models offer a reductionist 229 system in which to define HLA-restricted epitopes of relevance to humans carrying the 230 same alleles. Using these transgenic models in protein and peptide immunisation we were 231 able to build a comprehensive picture of immunodominant HLA class II restricted 232 epitopes derived from PA. Mice were immunised with the recombinant PA protein and 233 draining lymph node cells were restimulated with a peptide library spanning the PA 234 sequence (73 peptides in total, with some peptides overlapping the boundaries between 235 domains: domain 1 = PA 1-20 to PA 241-260; domain 2 = PA 251-270 to PA 471-490; 236 domain 3 = PA 491-510 to PA 581-600; domain 4 = PA 591-610 to PA 716-735,). After 237 immunisation with the recombinant protein of interest, all HLA transgenic mice 238 responded to the whole rPA (Fig 3) , but the response to the individual peptides was found 239 to be HLA-specific. 240 13 241 We investigated whether there might be any correlation between susceptibility of the 242 HLA transgenic lines to challenge and the breadth of T cell epitope recognition. Antigen-243 specific T cell responses to all stimulatory peptides were further investigated by peptide 244 immunisation and screening (Figs S1, S2 and S3). In total, 6 HLA-DR1 restricted 245 epitopes were identified: PA [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] 246 and PA 681-700 ( Fig 3A and Fig S3) . In comparison 14 HLA-DQ8 restricted epitopes 247 were identified: 249 PA 711-730, and PA 716-735 ( Fig 3B and Fig S1) : and 15 HLA-DR4 restricted epitopes 250 were identified: PA [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] 660, PA 681-700, and PA 711-730 ( Fig 3C and Fig S2) . Whilst some of these epitopes 253 were recognised by more than one HLA type (PA 331-350, PA 591-610, PA 601-620 and 254 PA 711-730 were constituents of both DR4 and DQ8 responses, while PA 371-390 and 255 PA 681-700 were recognised by both DR1 and DR4 alleles), no one epitope was found to 256 provoke a response in all 3 HLA alleles tested. Thus, it was noteworthy that HLA-DR1 257 transgenic mice, which were the least susceptible to anthrax challenge, responded to 258 fewer epitopes with a reduced repertoire of CD4+ T cell recognition than the other HLA 259 alleles screened. 1-20 11-30 21-40 31-50 41-60 51-70 61-80 71-90 81-100 91-110 101-120 111-130 121-140 131-150 141-160 151-170 168-187 171-190 181-200 191-210 201-220 211-230 221-240 231-250 241-260 251-270 261-280 271-290 281-300 291-310 301-320 311-330 321-340 331-350 341-360 351-370 361-380 371-390 381-400 391-410 401-420 411-430 421-440 431-450 441-460 451-470 461-480 471-490 The differential PA peptide binding across distinct HLA polymorphisms 264 Overlapping 20-mer peptides that represented the whole PA protein sequence were 265 evaluated for binding affinity to seven common HLA-DR alleles and two common HLA-266 DQ alleles (Table 1 ). The two epitopes that were recognised by multiple individuals from 267 the infected cohort (PA 168-187 and PA 651-670) showed a complete disparity in their 268 HLA binding affinities. Whilst PA 168-187 was not recognised by any of the transgenic 269 lines and showed an exceptionally low binding affinity across all HLA-DR alleles tested, 270 PA 651-670 showed strong-to-moderate binding across all HLA-DR alleles, and bound 271 strongly to HLA-DQ8, which also correlated with a strong response seen in the 272 corresponding transgenic line. Overall, we were not able to identify a propensity towards 273 a strong HLA binding affinity in those epitopes that were a feature of the infected concern in relation to vaccine efficacy and vaccine confidence. differences in susceptibility due to HLA polymorphisms are unlikely to have imposed 335 evolutionary selection pressure in anthrax-exposed human populations. The pathogen is 336 rarely transmitted from human-to-human, outbreaks tend to be of a limited nature (such 337 as a local community consuming the same contaminated livestock), and most cases are 338 not fatal. The greater concern relates to potential gaps in the efficacy of large-scale 339 vaccination programmes for biodefense purposes, such as in the US military. The colour bar at the right indicates the percentage of donors responding to a given 821 epitope, with shading from white (0%) to dark blue (50%). 
